Clinical Trial Update: Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety of combining navitoclax with sorafenib tosylate in patients with relapsed or refractory solid tumors, including hepatocellul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Hepatitis B
• Hepatitis C
• Hepatocellular Carcinoma

Drugs mentioned

• Navitoclax (navitoclax)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cirrhosis, Hepatitis B Infection | Phase 1 | Status: COMPLETED